{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:24:50Z","timestamp":1778750690862,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffman La-Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40123-026-01346-9","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:45:02Z","timestamp":1773920702000},"page":"1647-1670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7232-2989","authenticated-orcid":false,"given":"Yaneth","family":"Gil-Rojas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-4402","authenticated-orcid":false,"given":"Luke","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8074-5480","authenticated-orcid":false,"given":"Sebastien","family":"Eymere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-4326","authenticated-orcid":false,"given":"Oliver","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1515-4130","authenticated-orcid":false,"given":"Marloes","family":"Bagijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"9","key":"1346_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29583","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-Related Macular Degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14(9):e29583. https:\/\/doi.org\/10.7759\/cureus.29583.","journal-title":"Cureus"},{"issue":"2","key":"1346_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"1346_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40123-024-01061-3","volume":"14","author":"A Loewenstein","year":"2025","unstructured":"Loewenstein A, Sylvanowicz M, Amoaku WM, Aslam T, Cheung CMG, Eldem B, et al. Global insights from patients, providers, and staff on challenges and solutions in managing neovascular age-related macular degeneration. Ophthalmol Ther. 2025;14(1):211\u201328.","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"1346_CR4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.healthpol.2022.10.009","volume":"126","author":"A Kollerup","year":"2022","unstructured":"Kollerup A, Wadmann S, Bek T, Kjellberg J. National clinical guidelines and treatment centralization do not guarantee consistency in healthcare delivery. A mixed-methods study of wet age-related macular degeneration treatment in Denmark. Health Policy. 2022;126(12):1291\u2013302. https:\/\/doi.org\/10.1016\/j.healthpol.2022.10.009.","journal-title":"Health Policy"},{"issue":"4","key":"1346_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/bjophthalmol-2019-314336","volume":"104","author":"S Resnikoff","year":"2020","unstructured":"Resnikoff S, Lansingh VC, Washburn L, Felch W, Gauthier T-M, Taylor HR, et al. Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): will we meet the needs? Br J Ophthalmol. 2020;104(4):588\u201392. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314336.","journal-title":"Br J Ophthalmol"},{"key":"1346_CR6","unstructured":"The Royal College of Ophthalmologists (RCOphth). Census report: Facing workforce shortages and backlogs in the aftermath of COVID-19: The 2022 census of the ophthalmology consultant, trainee and SAS workforce. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2023\/03\/2022-Ophthalmology-census-Facing-workforce-shortages-and-backlogs-in-the-aftermath-of-COVID-19.pdf. Accessed 15-Jul-2025"},{"key":"1346_CR7","unstructured":"The Royal College of Ophthalmologists (RCOphth). The way forward: Options to help meet demand for the current and future care of patients with eye disease. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/12\/RCOphth-The-Way-Forward-AMD-300117.pdf. Accessed 07-Aug-2025"},{"issue":"5","key":"1346_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bjophthalmol-2011-301109","volume":"96","author":"CG Owen","year":"2012","unstructured":"Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1346_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018289","volume":"7","author":"W Hollingworth","year":"2017","unstructured":"Hollingworth W, Jones T, Reeves BC, Peto T. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open. 2017;7(10):e018289. https:\/\/doi.org\/10.1136\/bmjopen-2017-018289.","journal-title":"BMJ Open"},{"key":"1346_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01646-3","author":"R Chopra","year":"2022","unstructured":"Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PA-O, Balaskas K, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye. 2022. https:\/\/doi.org\/10.1038\/s41433-021-01646-3.","journal-title":"Eye"},{"key":"1346_CR11","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/opth.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesb\u00f8ll C. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465\u201374. https:\/\/doi.org\/10.2147\/opth.S409103.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1346_CR12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s40123-025-01140-z","volume":"14","author":"M Shellvarajah","year":"2025","unstructured":"Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D. Adherence to anti-VEGF treatment in patients with neovascular age-related macular degeneration: a real-world study. Ophthalmol Ther. 2025;14(6):1261\u20139. https:\/\/doi.org\/10.1007\/s40123-025-01140-z.","journal-title":"Ophthalmol Ther"},{"key":"1346_CR13","unstructured":"National Institute for Health and Care Excellence (NICE). Age-related macular degeneration. https:\/\/www.nice.org.uk\/guidance\/ng82\/chapter\/recommendations. Accessed 07-Aug-2025"},{"key":"1346_CR14","unstructured":"The Royal College of Ophthalmologists (RCOphth). National Ophthalmology Database (NOD): Age-related Macular Degeneration (AMD) - Audit Data Set. https:\/\/nodaudit.org.uk\/sites\/default\/files\/2022-06\/AMD%20Audit%20Clinical%20Data%20Set.pdf. Accessed 07-Aug-2025"},{"issue":"9","key":"1346_CR15","first-page":"2388","volume":"59","author":"N Patel","year":"2018","unstructured":"Patel N, Stirrup S. The impact of anti-VEGF treatment delay on the visual acuity of patients with wet age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2018;59(9):2388.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1346_CR16","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00417-021-05174-4","volume":"259","author":"LG Stone","year":"2021","unstructured":"Stone LG, Grinton ME, Talks JS. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1773\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1346_CR17","unstructured":"The Royal College of Ophthalmologists (RCOpht). National Ophthalmology Database Audit: The third report of age-related macular degeneration audit (AMD). March, 2025. https:\/\/live-nod-audit.pantheonsite.io\/sites\/default\/files\/2025-03\/NOD%20Audit%20Full%20Annual%20Report%202025_Final%20%281%29.pdf. Accessed 15-Jul-2025"},{"issue":"10326","key":"1346_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"8","key":"1346_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen S-J, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"issue":"7","key":"1346_CR20","first-page":"4905","volume":"65","author":"D Varma","year":"2024","unstructured":"Varma D, Talks J, de Salvo G, Patel PJ, De Silva SR, Gale R, et al. Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD. Invest Ophthalmol Visual Sci. 2024;65(7):4905.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"1346_CR21","unstructured":"Wong D, editor Improving clinic capacity with faricimab. EMJ Innov. 2025;9[1][Suppl 1]:2\u201311. 24th Congress of the European Society of Retina Specialists (EURETINA) 2025; Barcelona, Spain."},{"key":"1346_CR22","unstructured":"The Royal College of Ophthalmologists (RCOpht). Ophthalmology workforce position statement, June 2025. https:\/\/www.rcophth.ac.uk\/news-views\/rcophth-calls-for-action-on-workforce-to-reduce-strain\/. Accessed 15-Jul-2025"},{"key":"1346_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2362278","author":"S Sivaprasad","year":"2024","unstructured":"Sivaprasad S, Bailey C, Downey L, Gilbert R, Gale R, Kotagiri A, et al. Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Curr Med Res Opin. 2024. https:\/\/doi.org\/10.1080\/03007995.2024.2362278.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1346_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s41669-024-00537-z","volume":"9","author":"P Thokala","year":"2025","unstructured":"Thokala P, Duarte H, Wright S, Husereau D, Durand-Zaleski I, Lindgren P, et al. Incorporating resource constraints in health economic evaluations: overview and methodological considerations. Pharmacoecon Open. 2025;9(2):161\u201378. https:\/\/doi.org\/10.1007\/s41669-024-00537-z.","journal-title":"Pharmacoecon Open"},{"key":"1346_CR25","unstructured":"Goodman CS, Nicholson L, Boysen M, Head P. Uncovering true value in capacity constrained health systems. ISPOR Europe 2024; 17 November 2024; Barcelona, Spain."},{"issue":"12","key":"1346_CR26","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1038\/s41433-022-02149-5","volume":"36","author":"R Gale","year":"2022","unstructured":"Gale R, Cox O, Keenan C, Chakravarthy U. Health technology assessment of new retinal treatments; the need to capture healthcare capacity issues. Eye. 2022;36(12):2236\u20138.","journal-title":"Eye"},{"issue":"10","key":"1346_CR27","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s40123-024-00999-8","volume":"13","author":"T Li","year":"2024","unstructured":"Li T, Berdunov V, Hamilton R, Gil-Rojas Y, B\u00fchrer C, Cox O, et al. Economic assessment in resource-constrained systems: individual-level simulation model in wet age-related macular degeneration and diabetic macular oedema. Ophthalmol Ther. 2024;13(10):2577\u201397.","journal-title":"Ophthalmol Ther"},{"issue":"8","key":"1346_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8):1077\u201384.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1346_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3560-5","volume":"18","author":"E Demir","year":"2018","unstructured":"Demir E, Southern D, Verner A, Amoaku W. A simulation tool for better management of retinal services. BMC Health Serv Res. 2018;18(1):759.","journal-title":"BMC Health Serv Res"},{"key":"1346_CR30","unstructured":"MacEwen C, Davis A, Chang L. GIRFT Programme National Specialty Report Ophthalmology. https:\/\/gettingitrightfirsttime.co.uk\/wp-content\/uploads\/2019\/12\/OphthalmologyReportGIRFT19S.pdf. Accessed 15-Jul-2025"},{"key":"1346_CR31","unstructured":"Commissioning Guidance. Age-related Macular Degeneration Services. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/08\/AMD-Services-Commissioning-Guidance-Recommendtions.pdf. Accessed 15-Jul-2025"},{"issue":"7","key":"1346_CR32","first-page":"4210","volume":"61","author":"EH Souied","year":"2020","unstructured":"Souied EH, Holz FG, Hykin PG, Midena E, Wolf S, Allmeier H, et al. Efficacy of intravitreal aflibercept treat-and-extend regimen over 2 years for neovascular age-related macular degeneration: ARIES study. Invest Ophthalmol Visual Sci. 2020;61(7):4210.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"1346_CR33","unstructured":"National Institute for Health and Care Excellence (NICE). British National Formulary. https:\/\/bnf.nice.org.uk\/. Accessed 12-Dec-2025"},{"issue":"10","key":"1346_CR34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.ophtha.2021.03.028","volume":"128","author":"V Kirthi","year":"2021","unstructured":"Kirthi V, Neffendorf JE, Navaratnam AV, Machin JT, Hingorani M, Briggs TW, et al. Litigation in ophthalmology against the National Health Service in England. Ophthalmology. 2021;128(10):1487\u20139.","journal-title":"Ophthalmology"},{"key":"1346_CR35","unstructured":"NHS England. Referral to treatment waiting times data (Ophthalmology, May 2025 monthly dataset). https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/referral-to-treatment-waiting-times\/. Accessed 15-Jul-2025"},{"issue":"12","key":"1346_CR36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaophthalmol.2024.4401","volume":"142","author":"N Paudel","year":"2024","unstructured":"Paudel N, Brady L, Stratieva P, Galvin O, Lui B, Van den Brande I, et al. Economic burden of late-stage age-related macular degeneration in Bulgaria, Germany, and the US. JAMA Ophthalmol. 2024;142(12):1123\u201330.","journal-title":"JAMA Ophthalmol"},{"key":"1346_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01180-5","author":"D Tabano","year":"2025","unstructured":"Tabano D, Watane A, Gale R, Cox O, Hill SR, Longworth L, et al. The economic burden of anti-vascular endothelial growth factor on patients and caregivers in the UK, Europe, and North America. Ophthalmol Ther. 2025. https:\/\/doi.org\/10.1007\/s40123-025-01180-5.","journal-title":"Ophthalmol Ther"},{"key":"1346_CR38","unstructured":"NHS England. Pay for doctors. https:\/\/www.healthcareers.nhs.uk\/explore-roles\/doctors\/pay-doctors. Accessed 09-Jul-2025"},{"key":"1346_CR39","unstructured":"British Medical Association (BMA). Pay scales for SAS doctors in England. https:\/\/www.bma.org.uk\/pay-and-contracts\/pay\/specialist-associate-specialist-and-specialty-doctors-pay-scales\/pay-scales-for-sas-doctors-in-england. Accessed 09-Jul-2025"},{"key":"1346_CR40","unstructured":"Messly. Locum Salary Calculator. https:\/\/www.messly.com\/calculator. Accessed 09-Jul-2025"},{"issue":"4","key":"1346_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057269","volume":"12","author":"DS Thomas","year":"2022","unstructured":"Thomas DS, Warwick A, Olvera-Barrios A, Egan C, Schwartz R, Patra S, et al. Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation model. BMJ Open. 2022;12(4):e057269.","journal-title":"BMJ Open"},{"issue":"2","key":"1346_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/IAE.0000000000000717","volume":"36","author":"MM Brown","year":"2016","unstructured":"Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S. Societal costs associated with neovascular age-related macular degeneration in the United States. Retina. 2016;36(2):285\u201398.","journal-title":"Retina"},{"issue":"5","key":"1346_CR43","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/bjophthalmol-2019-314446","volume":"104","author":"K Fasler","year":"2020","unstructured":"Fasler K, Fu DJ, Moraes G, Wagner S, Gokhale E, Kortuem K, et al. Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration. Br J Ophthalmol. 2020;104(5):684\u201390.","journal-title":"Br J Ophthalmol"},{"key":"1346_CR44","unstructured":"NHS England. National Cost Collection Data. https:\/\/www.england.nhs.uk\/. Accessed 14-Oct-2025"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01346-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01346-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01346-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:07:06Z","timestamp":1778749626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01346-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01346-9","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yaneth Gil-Rojas and Sebastien Eymere are employees of Inizio Ignite\u00a0Putnam which received funding from F. Hoffman-La Roche for conducting the study and preparation of the manuscript. Marloes Bagijn and Oliver Cox are employees of F. Hoffman-La Roche. Dr. Nicholson has received a research grant from Optos; financial support for consultancy from Bayer, AbbVie, Roche, and Boehringer Ingelheim; and travel and speaking honoraria from Bayer, Roche, and AbbVie. Although the sponsor was involved in the study design and critically reviewed the manuscript, the analysis, interpretation of data, and reporting of results were independently conducted by the authors without influence from F. Hoffmann-La Roche. All authors confirm adherence to ICMJE authorship criteria and affirm full control over data and manuscript content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies with publicly available data and does not contain any new studies with human participants or animals performed by any of the authors. An ethics committee approval was not required, as the work relied solely on publicly available, previously published data and did not involve any new research procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}